Summary
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
According to APO Research, The global Generic Injectables market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Generic Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Generic Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Generic Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Generic Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Generic Injectables include Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical and Auromedics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Generic Injectables, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Generic Injectables, also provides the revenue of main regions and countries. Of the upcoming market potential for Generic Injectables, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Generic Injectables revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Generic Injectables market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Generic Injectables revenue, projected growth trends, production technology, application and end-user industry.
Generic Injectables Segment by Company
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Generic Injectables Segment by Type
Small Molecule
Large Molecule
Generic Injectables Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
Generic Injectables Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectables.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Generic Injectables in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Generic Injectables company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Injectables revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
- Market Overview
- Product Definition
- Generic Injectables Market by Type
- Global Generic Injectables Market Size by Type, 2020 VS 2024 VS 2031
- Small Molecule
- Large Molecule
- Generic Injectables Market by Application
- Global Generic Injectables Market Size by Application, 2020 VS 2024 VS 2031
- Oncology
- Anesthesia
- Anti-Infectives
- Parenteral Nutrition
- Cardiovascular Diseases
- Assumptions and Limitations
- Study Goals and Objectives
- Generic Injectables Market Dynamics
- Generic Injectables Industry Trends
- Generic Injectables Industry Drivers
- Generic Injectables Industry Opportunities and Challenges
- Generic Injectables Industry Restraints
- Global Growth Perspective
- Global Generic Injectables Market Perspective (2020-2031)
- Global Generic Injectables Growth Trends by Region
- Global Generic Injectables Market Size by Region: 2020 VS 2024 VS 2031
- Global Generic Injectables Market Size by Region (2020-2025)
- Global Generic Injectables Market Size by Region (2026-2031)
- Competitive Landscape by Players
- Global Generic Injectables Revenue by Players
- Global Generic Injectables Revenue by Players (2020-2025)
- Global Generic Injectables Revenue Market Share by Players (2020-2025)
- Global Generic Injectables Players Revenue Share Top 10 and Top 5 in 2024
- Global Generic Injectables Key Players Ranking, 2023 VS 2024 VS 2025
- Global Generic Injectables Key Players Headquarters & Area Served
- Global Generic Injectables Players, Product Type & Application
- Global Generic Injectables Players Establishment Date
- Market Competitive Analysis
- Global Generic Injectables Market CR5 and HHI
- 2024 Generic Injectables Tier 1, Tier 2, and Tier 3
- Global Generic Injectables Revenue by Players
- Generic Injectables Market Size by Type
- Global Generic Injectables Revenue by Type (2020 VS 2024 VS 2031)
- Global Generic Injectables Revenue by Type (2020-2031)
- Global Generic Injectables Revenue Market Share by Type (2020-2031)
- Generic Injectables Market Size by Application
- Global Generic Injectables Revenue by Application (2020 VS 2024 VS 2031)
- Global Generic Injectables Revenue by Application (2020-2031)
- Global Generic Injectables Revenue Market Share by Application (2020-2031)
- Company Profiles
- Hospira (Pfizer Inc.)
- Hospira (Pfizer Inc.) Comapny Information
- Hospira (Pfizer Inc.) Business Overview
- Hospira (Pfizer Inc.) Generic Injectables Revenue and Gross Margin (2020-2025)
- Hospira (Pfizer Inc.) Generic Injectables Product Portfolio
- Hospira (Pfizer Inc.) Recent Developments
- Fresenius Kabi
- Fresenius Kabi Comapny Information
- Fresenius Kabi Business Overview
- Fresenius Kabi Generic Injectables Revenue and Gross Margin (2020-2025)
- Fresenius Kabi Generic Injectables Product Portfolio
- Fresenius Kabi Recent Developments
- Sandoz (Novartis)
- Sandoz (Novartis) Comapny Information
- Sandoz (Novartis) Business Overview
- Sandoz (Novartis) Generic Injectables Revenue and Gross Margin (2020-2025)
- Sandoz (Novartis) Generic Injectables Product Portfolio
- Sandoz (Novartis) Recent Developments
- Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals PLC Comapny Information
- Hikma Pharmaceuticals PLC Business Overview
- Hikma Pharmaceuticals PLC Generic Injectables Revenue and Gross Margin (2020-2025)
- Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio
- Hikma Pharmaceuticals PLC Recent Developments
- Dr. Reddy’s Laboratories Ltd
- Dr. Reddy’s Laboratories Ltd Comapny Information
- Dr. Reddy’s Laboratories Ltd Business Overview
- Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue and Gross Margin (2020-2025)
- Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio
- Dr. Reddy’s Laboratories Ltd Recent Developments
- Grifols
- Grifols Comapny Information
- Grifols Business Overview
- Grifols Generic Injectables Revenue and Gross Margin (2020-2025)
- Grifols Generic Injectables Product Portfolio
- Grifols Recent Developments
- Nichi-Iko Group (Sagent)
- Nichi-Iko Group (Sagent) Comapny Information
- Nichi-Iko Group (Sagent) Business Overview
- Nichi-Iko Group (Sagent) Generic Injectables Revenue and Gross Margin (2020-2025)
- Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio
- Nichi-Iko Group (Sagent) Recent Developments
- Teva Pharmaceutical
- Teva Pharmaceutical Comapny Information
- Teva Pharmaceutical Business Overview
- Teva Pharmaceutical Generic Injectables Revenue and Gross Margin (2020-2025)
- Teva Pharmaceutical Generic Injectables Product Portfolio
- Teva Pharmaceutical Recent Developments
- Auromedics
- Auromedics Comapny Information
- Auromedics Business Overview
- Auromedics Generic Injectables Revenue and Gross Margin (2020-2025)
- Auromedics Generic Injectables Product Portfolio
- Auromedics Recent Developments
- Sanofi
- Sanofi Comapny Information
- Sanofi Business Overview
- Sanofi Generic Injectables Revenue and Gross Margin (2020-2025)
- Sanofi Generic Injectables Product Portfolio
- Sanofi Recent Developments
- Gland Pharma
- Gland Pharma Comapny Information
- Gland Pharma Business Overview
- Gland Pharma Generic Injectables Revenue and Gross Margin (2020-2025)
- Gland Pharma Generic Injectables Product Portfolio
- Gland Pharma Recent Developments
- Endo International PLC
- Endo International PLC Comapny Information
- Endo International PLC Business Overview
- Endo International PLC Generic Injectables Revenue and Gross Margin (2020-2025)
- Endo International PLC Generic Injectables Product Portfolio
- Endo International PLC Recent Developments
- Hospira (Pfizer Inc.)
- North America
- North America Generic Injectables Revenue (2020-2031)
- North America Generic Injectables Revenue by Type (2020-2031)
- North America Generic Injectables Revenue by Type (2020-2025)
- North America Generic Injectables Revenue by Type (2026-2031)
- North America Generic Injectables Revenue Share by Type (2020-2031)
- North America Generic Injectables Revenue by Application (2020-2031)
- North America Generic Injectables Revenue by Application (2020-2025)
- North America Generic Injectables Revenue by Application (2026-2031)
- North America Generic Injectables Revenue Share by Application (2020-2031)
- North America Generic Injectables Revenue by Country
- North America Generic Injectables Revenue by Country (2020 VS 2024 VS 2031)
- North America Generic Injectables Revenue by Country (2020-2025)
- North America Generic Injectables Revenue by Country (2026-2031)
- United States
- Canada
- Mexico
- Europe
- Europe Generic Injectables Revenue (2020-2031)
- Europe Generic Injectables Revenue by Type (2020-2031)
- Europe Generic Injectables Revenue by Type (2020-2025)
- Europe Generic Injectables Revenue by Type (2026-2031)
- Europe Generic Injectables Revenue Share by Type (2020-2031)
- Europe Generic Injectables Revenue by Application (2020-2031)
- Europe Generic Injectables Revenue by Application (2020-2025)
- Europe Generic Injectables Revenue by Application (2026-2031)
- Europe Generic Injectables Revenue Share by Application (2020-2031)
- Europe Generic Injectables Revenue by Country
- Europe Generic Injectables Revenue by Country (2020 VS 2024 VS 2031)
- Europe Generic Injectables Revenue by Country (2020-2025)
- Europe Generic Injectables Revenue by Country (2026-2031)
- Germany
- France
- U.K.
- Italy
- Russia
- Spain
- Netherlands
- Switzerland
- Sweden
- Poland
- China
- China Generic Injectables Revenue (2020-2031)
- China Generic Injectables Revenue by Type (2020-2031)
- China Generic Injectables Revenue by Type (2020-2025)
- China Generic Injectables Revenue by Type (2026-2031)
- China Generic Injectables Revenue Share by Type (2020-2031)
- China Generic Injectables Revenue by Application (2020-2031)
- China Generic Injectables Revenue by Application (2020-2025)
- China Generic Injectables Revenue by Application (2026-2031)
- China Generic Injectables Revenue Share by Application (2020-2031)
- Asia (Excluding China)
- Asia Generic Injectables Revenue (2020-2031)
- Asia Generic Injectables Revenue by Type (2020-2031)
- Asia Generic Injectables Revenue by Type (2020-2025)
- Asia Generic Injectables Revenue by Type (2026-2031)
- Asia Generic Injectables Revenue Share by Type (2020-2031)
- Asia Generic Injectables Revenue by Application (2020-2031)
- Asia Generic Injectables Revenue by Application (2020-2025)
- Asia Generic Injectables Revenue by Application (2026-2031)
- Asia Generic Injectables Revenue Share by Application (2020-2031)
- Asia Generic Injectables Revenue by Country
- Asia Generic Injectables Revenue by Country (2020 VS 2024 VS 2031)
- Asia Generic Injectables Revenue by Country (2020-2025)
- Asia Generic Injectables Revenue by Country (2026-2031)
- Japan
- South Korea
- India
- Australia
- Taiwan
- Southeast Asia
- South America, Middle East and Africa
- SAMEA Generic Injectables Revenue (2020-2031)
- SAMEA Generic Injectables Revenue by Type (2020-2031)
- SAMEA Generic Injectables Revenue by Type (2020-2025)
- SAMEA Generic Injectables Revenue by Type (2026-2031)
- SAMEA Generic Injectables Revenue Share by Type (2020-2031)
- SAMEA Generic Injectables Revenue by Application (2020-2031)
- SAMEA Generic Injectables Revenue by Application (2020-2025)
- SAMEA Generic Injectables Revenue by Application (2026-2031)
- SAMEA Generic Injectables Revenue Share by Application (2020-2031)
- SAMEA Generic Injectables Revenue by Country
- SAMEA Generic Injectables Revenue by Country (2020 VS 2024 VS 2031)
- SAMEA Generic Injectables Revenue by Country (2020-2025)
- SAMEA Generic Injectables Revenue by Country (2026-2031)
- Brazil
- Argentina
- Chile
- Colombia
- Peru
- Saudi Arabia
- Israel
- UAE
- Turkey
- Iran
- Egypt
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
- Disclaimer
List of Tables
Table 1 | :Global Generic Injectables Market Size Growth Rate by Type (US$ Million), 2020 VS 2024 VS 2031 |
Table 2 | :Small Molecule Major Player |
Table 3 | :Large Molecule Major Player |
Table 4 | :Global Generic Injectables Market Size Growth Rate by Application (US$ Million), 2020 VS 2024 VS 2031 |
Table 5 | :Oncology Major Player |
Table 6 | :Anesthesia Major Player |
Table 7 | :Anti-Infectives Major Player |
Table 8 | :Parenteral Nutrition Major Player |
Table 9 | :Cardiovascular Diseases Major Player |
Table 10 | :Generic Injectables Industry Trends |
Table 11 | :Generic Injectables Industry Drivers |
Table 12 | :Generic Injectables Industry Opportunities and Challenges |
Table 13 | :Generic Injectables Industry Restraints |
Table 14 | :Global Generic Injectables Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031 |
Table 15 | :Global Generic Injectables Market Size by Region (2020-2025) & (US$ Million) |
Table 16 | :Global Generic Injectables Market Share by Region (2020-2025) |
Table 17 | :Global Generic Injectables Market Size by Region (2026-2031) & (US$ Million) |
Table 18 | :Global Generic Injectables Market Share by Region (2026-2031) |
Table 19 | :Global Generic Injectables Revenue by Players (US$ Million) & (2020-2025) |
Table 20 | :Global Generic Injectables Revenue Market Share by Players (2020-2025) |
Table 21 | :Global Generic Injectables Key Players Ranking, 2023 VS 2024 VS 2025 |
Table 22 | :Global Generic Injectables Key Players Headquarters & Area Served |
Table 23 | :Global Generic Injectables Players, Product Type & Application |
Table 24 | :Global Generic Injectables Players Establishment Date |
Table 25 | :Global Players Market Concentration Ratio (CR5 and HHI) |
Table 26 | :Global Generic Injectables by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024) |
Table 27 | :Global Generic Injectables Revenue by Type 2020 VS 2024 VS 2031 (US$ Million) |
Table 28 | :Global Generic Injectables Revenue by Type (2020-2025) & (US$ Million) |
Table 29 | :Global Generic Injectables Revenue by Type (2026-2031) & (US$ Million) |
Table 30 | :Global Generic Injectables Revenue Market Share by Type (2020-2025) & (US$ Million) |
Table 31 | :Global Generic Injectables Revenue Market Share by Type (2026-2031) & (US$ Million) |
Table 32 | :Global Generic Injectables Revenue by Application 2020 VS 2024 VS 2031 (US$ Million) |
Table 33 | :Global Generic Injectables Revenue by Application (2020-2025) & (US$ Million) |
Table 34 | :Global Generic Injectables Revenue by Application (2026-2031) & (US$ Million) |
Table 35 | :Global Generic Injectables Revenue Market Share by Application (2020-2025) & (US$ Million) |
Table 36 | :Global Generic Injectables Revenue Market Share by Application (2026-2031) & (US$ Million) |
Table 37 | :Hospira (Pfizer Inc.) Company Information |
Table 38 | :Hospira (Pfizer Inc.) Business Overview |
Table 39 | :Hospira (Pfizer Inc.) Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 40 | :Hospira (Pfizer Inc.) Generic Injectables Product Portfolio |
Table 41 | :Hospira (Pfizer Inc.) Recent Development |
Table 42 | :Fresenius Kabi Company Information |
Table 43 | :Fresenius Kabi Business Overview |
Table 44 | :Fresenius Kabi Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 45 | :Fresenius Kabi Generic Injectables Product Portfolio |
Table 46 | :Fresenius Kabi Recent Development |
Table 47 | :Sandoz (Novartis) Company Information |
Table 48 | :Sandoz (Novartis) Business Overview |
Table 49 | :Sandoz (Novartis) Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 50 | :Sandoz (Novartis) Generic Injectables Product Portfolio |
Table 51 | :Sandoz (Novartis) Recent Development |
Table 52 | :Hikma Pharmaceuticals PLC Company Information |
Table 53 | :Hikma Pharmaceuticals PLC Business Overview |
Table 54 | :Hikma Pharmaceuticals PLC Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 55 | :Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio |
Table 56 | :Hikma Pharmaceuticals PLC Recent Development |
Table 57 | :Dr. Reddy’s Laboratories Ltd Company Information |
Table 58 | :Dr. Reddy’s Laboratories Ltd Business Overview |
Table 59 | :Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 60 | :Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio |
Table 61 | :Dr. Reddy’s Laboratories Ltd Recent Development |
Table 62 | :Grifols Company Information |
Table 63 | :Grifols Business Overview |
Table 64 | :Grifols Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 65 | :Grifols Generic Injectables Product Portfolio |
Table 66 | :Grifols Recent Development |
Table 67 | :Nichi-Iko Group (Sagent) Company Information |
Table 68 | :Nichi-Iko Group (Sagent) Business Overview |
Table 69 | :Nichi-Iko Group (Sagent) Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 70 | :Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio |
Table 71 | :Nichi-Iko Group (Sagent) Recent Development |
Table 72 | :Teva Pharmaceutical Company Information |
Table 73 | :Teva Pharmaceutical Business Overview |
Table 74 | :Teva Pharmaceutical Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 75 | :Teva Pharmaceutical Generic Injectables Product Portfolio |
Table 76 | :Teva Pharmaceutical Recent Development |
Table 77 | :Auromedics Company Information |
Table 78 | :Auromedics Business Overview |
Table 79 | :Auromedics Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 80 | :Auromedics Generic Injectables Product Portfolio |
Table 81 | :Auromedics Recent Development |
Table 82 | :Sanofi Company Information |
Table 83 | :Sanofi Business Overview |
Table 84 | :Sanofi Generic Injectables Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 85 | :Sanofi Generic Injectables Product Portfolio |
Table 86 | :Sanofi Recent Development |
Table 87 | :Gland Pharma Company Information |
Table 88 | :Gland Pharma Business Overview |
Table 89 | :Gland Pharma Generic Injectables Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 90 | :Gland Pharma Generic Injectables Product Portfolio |
Table 91 | :Gland Pharma Recent Development |
Table 92 | :Endo International PLC Company Information |
Table 93 | :Endo International PLC Business Overview |
Table 94 | :Endo International PLC Generic Injectables Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 95 | :Endo International PLC Generic Injectables Product Portfolio |
Table 96 | :Endo International PLC Recent Development |
Table 97 | :North America Generic Injectables Revenue by Type (2020-2025) & (US$ Million) |
Table 98 | :North America Generic Injectables Revenue by Application (2020-2025) & (US$ Million) |
Table 99 | :North America Generic Injectables Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 100 | :North America Generic Injectables Revenue by Country (2020-2025) & (US$ Million) |
Table 101 | :North America Generic Injectables Revenue by Country (2026-2031) & (US$ Million) |
Table 102 | :Europe Generic Injectables Revenue by Type (2020-2025) & (US$ Million) |
Table 103 | :Europe Generic Injectables Revenue by Application (2020-2025) & (US$ Million) |
Table 104 | :Europe Generic Injectables Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 105 | :Europe Generic Injectables Revenue by Country (2020-2025) & (US$ Million) |
Table 106 | :Europe Generic Injectables Revenue by Country (2026-2031) & (US$ Million) |
Table 107 | :China Generic Injectables Revenue by Type (2020-2025) & (US$ Million) |
Table 108 | :China Generic Injectables Revenue by Application (2020-2025) & (US$ Million) |
Table 109 | :Asia Generic Injectables Revenue by Type (2020-2025) & (US$ Million) |
Table 110 | :Asia Generic Injectables Revenue by Application (2020-2025) & (US$ Million) |
Table 111 | :Asia Generic Injectables Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 112 | :Asia Generic Injectables Revenue by Country (2020-2025) & (US$ Million) |
Table 113 | :Asia Generic Injectables Revenue by Country (2026-2031) & (US$ Million) |
Table 114 | :SAMEA Generic Injectables Revenue by Type (2020-2025) & (US$ Million) |
Table 115 | :SAMEA Generic Injectables Revenue by Application (2020-2025) & (US$ Million) |
Table 116 | :SAMEA Generic Injectables Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 117 | :SAMEA Generic Injectables Revenue by Country (2020-2025) & (US$ Million) |
Table 118 | :SAMEA Generic Injectables Revenue by Country (2026-2031) & (US$ Million) |
Table 119 | :Research Programs/Design for This Report |
Table 120 | :Authors List of This Report |
Table 121 | :Secondary Sources |
Table 122 | :Primary Sources |
List of Figures
Figure 1 | :Generic Injectables Image |
Figure 2 | :Global Generic Injectables Market Size Growth Rate by Type (US$ Million), 2020 VS 2024 VS 2031 |
Figure 3 | :Global Generic Injectables Market Size Share 2020 VS 2024 VS 2031 |
Figure 4 | :Small Molecule Image |
Figure 5 | :Large Molecule Image |
Figure 6 | :Global Generic Injectables Market Size Growth Rate by Application (US$ Million), 2020 VS 2024 VS 2031 |
Figure 7 | :Global Generic Injectables Market Size Share 2020 VS 2024 VS 2031 |
Figure 8 | :Oncology Image |
Figure 9 | :Anesthesia Image |
Figure 10 | :Anti-Infectives Image |
Figure 11 | :Parenteral Nutrition Image |
Figure 12 | :Cardiovascular Diseases Image |
Figure 13 | :Global Generic Injectables Market Size (US$ Million) & (2020-2031) |
Figure 14 | :Global Generic Injectables Market Size, (US$ Million), 2020 VS 2024 VS 2031 |
Figure 15 | :Global Generic Injectables Market Share by Region: 2020 VS 2024 VS 2031 |
Figure 16 | :Global Generic Injectables Players Revenue Share Top 10 and Top 5 in 2024 |
Figure 17 | :Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
Figure 18 | :Global Generic Injectables Revenue by Type (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 19 | :Global Generic Injectables Revenue Market Share 2020 VS 2024 VS 2031 |
Figure 20 | :Global Generic Injectables Revenue Market Share by Type (2020-2031) |
Figure 21 | :Global Generic Injectables Revenue by Application (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 22 | :Global Generic Injectables Revenue Market Share by Application (2020 VS 2024 VS 2031) |
Figure 23 | :Global Generic Injectables Revenue Market Share by Application (2020-2031) |
Figure 24 | :North America Generic Injectables Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 25 | :North America Generic Injectables Revenue by Type (2026-2031) & (US$ Million) |
Figure 26 | :North America Generic Injectables Revenue Share by Type (2020-2031) |
Figure 27 | :North America Generic Injectables Revenue by Application (2026-2031) & (US$ Million) |
Figure 28 | :North America Generic Injectables Revenue Share by Application (2020-2031) |
Figure 29 | :North America Generic Injectables Revenue Share by Country (2020-2031) |
Figure 30 | :United States Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 31 | :Canada Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 32 | :Mexico Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 33 | :Europe Generic Injectables Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 34 | :Europe Generic Injectables Revenue by Type (2026-2031) & (US$ Million) |
Figure 35 | :Europe Generic Injectables Revenue Share by Type (2020-2031) |
Figure 36 | :Europe Generic Injectables Revenue by Application (2026-2031) & (US$ Million) |
Figure 37 | :Europe Generic Injectables Revenue Share by Application (2020-2031) |
Figure 38 | :Europe Generic Injectables Revenue Share by Country (2020-2031) |
Figure 39 | :Germany Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 40 | :France Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 41 | :U.K. Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 42 | :Italy Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 43 | :Spain Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 44 | :Russia Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 45 | :Netherlands Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 46 | :Nordic Countries Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 47 | :China Generic Injectables Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 48 | :China Generic Injectables Revenue by Type (2026-2031) & (US$ Million) |
Figure 49 | :China Generic Injectables Revenue Share by Type (2020-2031) |
Figure 50 | :China Generic Injectables Revenue by Application (2026-2031) & (US$ Million) |
Figure 51 | :China Generic Injectables Revenue Share by Application (2020-2031) |
Figure 52 | :Asia Generic Injectables Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 53 | :Asia Generic Injectables Revenue by Type (2026-2031) & (US$ Million) |
Figure 54 | :Asia Generic Injectables Revenue Share by Type (2020-2031) |
Figure 55 | :Asia Generic Injectables Revenue by Application (2026-2031) & (US$ Million) |
Figure 56 | :Asia Generic Injectables Revenue Share by Application (2020-2031) |
Figure 57 | :Asia Generic Injectables Revenue Share by Country (2020-2031) |
Figure 58 | :Japan Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 59 | :South Korea Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 60 | :India Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 61 | :Australia Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 62 | :Taiwan Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 63 | :Southeast Asia Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 64 | :SAMEA Generic Injectables Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 65 | :SAMEA Generic Injectables Revenue by Type (2026-2031) & (US$ Million) |
Figure 66 | :SAMEA Generic Injectables Revenue Share by Type (2020-2031) |
Figure 67 | :SAMEA Generic Injectables Revenue by Application (2026-2031) & (US$ Million) |
Figure 68 | :SAMEA Generic Injectables Revenue Share by Application (2020-2031) |
Figure 69 | :SAMEA Generic Injectables Revenue Share by Country (2020-2031) |
Figure 70 | :Brazil Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 71 | :Argentina Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 72 | :Chile Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 73 | :Colombia Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 74 | :Peru Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 75 | :Saudi Arabia Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 76 | :Israel Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 77 | :UAE Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 78 | :Turkey Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 79 | :Iran Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 80 | :Egypt Generic Injectables Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 81 | :Years Considered |
Figure 82 | :Research Process |
Figure 83 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Medical Care
Global Generic Injectables Market Analysis and Forecast 2025-2031
Pages: 193
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.